04X Stock Overview
Develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Personalis, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.65 |
| 52 Week High | US$6.86 |
| 52 Week Low | US$0.94 |
| Beta | 1.74 |
| 1 Month Change | 1.79% |
| 3 Month Change | 28.63% |
| 1 Year Change | 285.58% |
| 3 Year Change | -47.41% |
| 5 Year Change | n/a |
| Change since IPO | -75.76% |
Recent News & Updates
Recent updates
Shareholder Returns
| 04X | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | -4.3% | -0.9% | 2.7% |
| 1Y | 285.6% | -4.2% | 17.0% |
Return vs Industry: 04X exceeded the German Life Sciences industry which returned -4.2% over the past year.
Return vs Market: 04X exceeded the German Market which returned 17% over the past year.
Price Volatility
| 04X volatility | |
|---|---|
| 04X Average Weekly Movement | 24.4% |
| Life Sciences Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.1% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 04X's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 04X's weekly volatility (24%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 224 | Chris Hall | www.personalis.com |
Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample.
Personalis, Inc. Fundamentals Summary
| 04X fundamental statistics | |
|---|---|
| Market cap | €372.93m |
| Earnings (TTM) | -€87.15m |
| Revenue (TTM) | €83.38m |
4.5x
P/S Ratio-4.3x
P/E RatioIs 04X overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 04X income statement (TTM) | |
|---|---|
| Revenue | US$87.49m |
| Cost of Revenue | US$60.01m |
| Gross Profit | US$27.48m |
| Other Expenses | US$118.92m |
| Earnings | -US$91.44m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 27, 2025
| Earnings per share (EPS) | -1.29 |
| Gross Margin | 31.41% |
| Net Profit Margin | -104.52% |
| Debt/Equity Ratio | 1.0% |
How did 04X perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/16 03:40 |
| End of Day Share Price | 2025/02/14 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Personalis, Inc. is covered by 13 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Derik de Bruin | BofA Global Research |
| Mark Massaro | BTIG |
| Patrick Donnelly | Citigroup Inc |